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Abstract  
 
Rationale Mephedrone (4-methylmethcathinone) is a still poorly known drug of abuse, 
alternative to ecstasy or cocaine. 
 
Objective The major aims were to investigate the pharmacokinetics and locomotor 
activity of mephedrone in rats and provide a pharmacokinetic/pharmacodynamic model. 
 
Methods Mephedrone was administered to male Sprague-Dawley rats intravenously (10 
mg/kg) and orally (30 and 60 mg/kg). Plasma concentrations and metabolites were 
characterized by LC/MS and LC–MS/MS fragmentation patterns. Locomotor activity 
was monitored for 180-240 min. 
 
Results Mephedrone plasma concentrations after i.v. administration fit to a two-
compartment model (α=10.23 h-1 and β=1.86 h-1). After oral administration, peak 
mephedrone concentrations were achieved between 0.5-1 h, and declined to 
undetectable levels at 9 h. Absolute bioavailability of mephedrone was of about 10% 
and the percentage of mephedrone protein binding was of 21.59 ± 3.67%. We have 
identified five Phase I metabolites in rat blood after oral administration. The 
relationship between brain levels and free plasma concentration was 1.85 ± 0.08. 
Mephedrone induced a dose-dependent increase in locomotor activity, which lasted up 
to 2 h. The pharmacokinetic-pharmacodynamic model successfully describes the 
relationship between mephedrone plasma concentrations and its psychostimulant effect.  
 
Conclusions We suggest a very important first-pass effect for mephedrone after oral 
administration and an easy access to the central nervous system.  The model described 
might be useful in the estimation and prediction of the onset, magnitude and time course 
of mephedrone pharmacodynamics as well as to design new animal models of 
mephedrone addiction and toxicity. 
 
 
Key words: Mephedrone; Pharmacokinetics; Locomotor activity; PK/PD modeling; 
Rat. 
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Introduction 
 
Mephedrone is a synthetic ring-substituted cathinone closely related to the 
phenethylamine family, differing only by a keto functional group at the beta carbon. It 
can be purchased online or from street-dealers. On the Internet, mephedrone is often 
marketed as ‘plant food’, ‘bath salt" or ‘research chemical’. The rapid rise in popularity 
of mephedrone may reflect growing user dissatisfaction with the purity and availability 
of MDMA (ecstasy) or its chemical precursors and cocaine. Mephedrone appears to be 
used by several population groups, including people involved in the dance and music 
scene, as well as mainstream young adults, and adolescents (Schifano et al. 2011). 
 
Mephedrone is known to have similar effects to other psychostimulant drugs (Brunt 
et al. 2012; Varner et al. 2012). There are two reported fatalities in the European Union 
in which mephedrone appears to be the sole cause of death and there are at least another 
37 deaths in which mephedrone have been detected in post-mortem samples (Maskell et 
al. 2011). Mephedrone was the first cathinone derivative to be ‘risk-assessed’ by the 
extended Scientific Committee of the EMCDDA (European Monitoring Centre for 
Drugs and Drug Addiction). 
 
Information on mephedrone human pharmacokinetics is limited to user reports. From 
these, it appears that both the desired and adverse effects of mephedrone are similar to 
those found for MDMA and cocaine (Wood et al. 2010b). However, its relatively short 
duration of action, which lead to repeated dosing, is more similar to cocaine (Wilkinson 
et al. 1980). In a recent study, 70 % of mephedrone users reported to be using it by nasal 
insufflation, while 30 % admitted to be taking it orally (Dickson et al. 2010; Winstock 
et al. 2011). There are numerous reports of individuals using mixed routes during a 
single session. Moreover, there are increasing reports of intravenous injection and there 
is also one case report from the UK of an individual who developed acute mephedrone 
toxicity after an intramuscular injection of dissolved powder (Wood et al. 2010a).  
 
Users report on Internet forums that desired effects are typically seen within 15–45 
minutes after oral ingestion and stated that the onset of action is slower when 
mephedrone is taken orally on a full stomach. Users also report onset of action to be 
within a few minutes following nasal insufflation, with peak desired effects after 30 
 4 
 
minutes. Desired effects last approximately 2–3 hours; this leads users to redoes during 
a single session to extend the duration of the desired effects. 
 
Studies on the pharmacokinetics of mephedrone in rats are very scarce. Meyer et al. 
(2010) suggested the most probable metabolites of mephedrone present in the urine. In 
this study mephedrone was administered orally and urine was collected over a 24-hour 
period. Hadlock et al. (2011) assessed mephedrone concentrations in rat brain and 
plasma 1 h after a binge treatment and more recently (Khreit et al. 2012) investigated 
the in vitro metabolism of mephedrone in rat isolated hepatocytes. 
 
The current studies were designed to investigate the pharmacokinetic profile and 
pharmacodynamic response to mephedrone in rats after its acute administration by 
intravenous and oral route at different doses by using a highly sensitive and specific 
analytical methodology, based on liquid chromatography/mass spectrometry/mass 
spectrometry (LC/MS/MS). Results from this study might provide useful tools in order 
to design new animal models of mephedrone addiction and toxicity. This objective was 
first pursued by constructing a pharmacokinetic/pharmacodynamics (PK/PD) model for 
mephedrone in rats in order to obtain basic guidelines for human risk assessment. In this 
study the following main pharmacokinetic parameters were estimated: total area under 
the curve (AUC0-∞), apparent volume of distribution at steady state (Vss), total plasma 
clearance (Clp), metabolic clearance (Clmet), and elimination half-life (t1/2β). The 
pharmacodynamic studies described herein focused on the evaluation of the 
psychostimulant effect of this drug of abuse, and trying to establish a correlation 
between the hyperlocomotion induced by mephedrone and its plasma levels. 
Furthermore, another goal of this study was to analyze the metabolic pathway of 
mephedrone and its brain concentration after an oral administration as well as to 
establish a relationship between mephedrone brain concentration and its 
psychostimulant effect.  
 
Materials and methods 
Drugs  
Pure racemic mephedrone and methylone HCl were synthetized and characterized by us 
as described previously (López-Arnau et al. 2012). Mephedrone solutions for injection 
were prepared in saline immediately before administration. Isoflurane was from 
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Laboratorios Dr. Esteve (Barcelona, Spain). Reagents required for LC/MS assays were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). 
 
Animals 
 
The Experimental protocols for the use of animals in this study were approved by the 
Animal Ethics Committee of the University of Barcelona, following the guidelines of 
the European Community Council (86/609/EEC). Male Sprague Dawley rats (Janvier, 
Le Génest, France) weighing 225-250 g were used. Animals were housed at 22 ± 1 ºC 
under a 12 h light/dark cycle with free access to food and drinking water. 
 
Pharmacokinetic experiments 
 
For intravenous pharmacokinetic analysis, mephedrone was administered at a dose of 
10 mg/kg. For oral pharmacokinetic experiments, mephedrone was administered at 
doses of 30 and 60 mg/kg to rats previously fasted for 18 h. 
 
Blood samples were collected from isoflurane anesthetized rats in a time schedule from 
0.08 to 9 h and transferred to 1 ml glass tubes with 7.5% EDTA on ice. After each blood 
extraction, an equal volume of saline was infused to maintain homeostasis. In some 
animals, blood samples and the whole brain were obtained simultaneously 45 min after 
oral administration (dose of 30 mg/kg).  
 
90 µl of plasma samples were mixed with 10 µl of internal standard (IS) solution 
(methylone, 200 ng/ml). The mixture was extracted with methanol (to a final 
concentration of 70%) and after centrifugation (10,000 x g for 5 min), supernatant was 
acidified (Sørensen et al. 2011), filtered (Microcon 30, Millipore, Bedford, MA, USA) 
and transferred to an auto sampler vial. 
An HP Agilent Technologies 1100 LC system equipped with an auto sampler and a 
column oven set to 40 oC and coupled API 3000 triple-quadrupole MS (AB Sciex) with 
a turbo ion spray source was used to quantify the corresponding cathinone. 
Chromatographic separation was achieved on a Luna HST C18 (100 x 2mm i.d.: 2.5 
µm) column and controlled by Analyst software. The mobile phase was water (A) and 
methanol (B) with 0.1% of formic acid in both solvents. An increasing linear gradient 
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(v/v) of B was used (t(min),%B), as follows: (0, 5), (20, 95), (22, 95), (22.5, 5) and 
(32.5, 5), at a constant flow rate (150 µl/min). The biological samples were refrigerated 
at 4 oC in the auto sampler and 5 µl were injected into the LC-MS/MS system. The LC-
ESI (electrospray ionization)-MS/MS conditions were optimized by direct infusion of 
cathinone standards (1 µg/ml) dissolved in 50:50 (v/v) water (0.1% formic 
acid)/methanol (0.1% formic acid) into the MS at a constant flow rate (5 µl/min). The 
turbo ion spray source was used in positive mode with a capillary voltage of +4500 V 
and N2 as nebulizer gas. For mephedrone one transition was followed (m/z 178.1→160.0) 
(collision energy of 17 V). Two transitions were followed for methylone (m/z 
208.1→190.1; 208.1→160.0) (collision energies of 17 and 22 V respectively), and both 
were used for the quantification.  
 
Blood Metabolite determination 
 
Blood samples were collected at 30, 60 and 120 min after oral administration at a dose 
of 30 mg/kg. The metabolite samples were treated as described above, without IS. For 
the metabolite identification, a Linear Trap Quadrupole Orbitrap Velos MS equipped 
with an ESI source was used, coupled to an Accela chromatograph, a refrigerated auto 
sampler and a photodiode array detector (Thermo Scientific, Hemel Hempstead, U.K.). 
Chromatographic separation was achieved on a Luna C18 (100 x 2.1mm, i.d.: 3µm) 
column. The mobile phase was the same as the one used in the pharmacokinetic studies 
with an increasing linear gradient (v/v) of B (t(min),%B), as follows: (0, 2), (20, 95), 
(22, 95), (25, 2) and (30, 2) at a constant flow rate (150 µl/min). The injection volume 
was 10 µl. Data were acquired in Fourier transform mass spectrometry mode (FT MS). 
Operation parameters were as follow: source voltage, 3.5(kV) in positive or negative ion 
mode; S-Lens RF levels, 60%; capillary temperature was fixed at 275 oC; sheath gas at 
40 (arbitrary units) and auxiliary gas at 10 (arbitrary units). MS2 acquisition was carried 
out using collision energy between 35 and 50%.  
 
Protein binding and brain levels 
  
In protein binding experiments samples were divided in two. One half was filtered 
through centrifugal filter units (Centrifree YM-30, Millipore) for comparison with the 
other unfiltered half.  Plasma samples were extracted as described above. The extraction 
 7 
 
of brain samples was carried out as described by Hadlock et al. (2011) and brain 
mephedrone levels and protein binding assays were quantified as described in the 
pharmacokinetic experiments. 
 
Calibration 
 
Plasma and brains from untreated rats were used to obtain the calibration curves. In the 
plasma analysis, seven standards were prepared daily in 100 µl of blank plasma (from 
10 to 6,000 ng/ml). To determine brain mephedrone levels, five standards were 
prepared, also daily, in 0.5 ml of brain homogenate (from 10 to 250 ng/ml). Methylone 
was used as IS at the final concentration of 200 ng/ml for plasma levels and 50 ng/ml 
for brain levels. The method showed linearity within the concentration range studied 
and the limit of quantification was considered lower than 10 ng/ml. Quality control 
samples were prepared at 50, 1,000, 5,000 ng/ml and 20, 50, 200 ng/ml for plasma and 
brain analysis, respectively. The accuracy of the assay was 90 - 110% and t0he intra- 
and inter-assay coefficients of variation (CV) were less than 15%.  
 
Locomotor activity experiments 
 
Prior to experiments, animals received two habituation sessions (48 and 24 h before 
testing). During these sessions, each rat was intravenously or orally administered saline 
and placed in a Plexiglas cage. This cage constituted the activity box that was later 
placed inside a frame system of two sets of 16 infrared photocells (LE8811, PANLAB, 
Barcelona, Spain) mounted according to the x, y axis coordinates and 2.5 cm above the 
wire mesh floor. Occlusions of the photo beams were recorded and sent to a 
computerized system (SedaCom32, PANLAB, Barcelona, Spain). The interruption 
counts, over a 10 min-block, were used as a measure of horizontal locomotor activity. 
After intravenous or oral drug administration, locomotor activity was monitored for 180 
min and 240 min, respectively. On the testing day, the animals received mephedrone 
intravenously (10 mg/kg), or orally (30 or 60 mg/kg), and were immediately placed in 
the activity box. Registration of horizontal locomotor activity then began.  
 
Pharmacokinetic/pharmacodynamic modeling 
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PKPD analysis was carried out on mean and standard deviation data. Because 
experimental data were obtained in parallel assays, data fitting were performed with the 
aggregates of the different doses (data pooling) in order to estimate a unique set of 
parameters. Assessment of the relative goodness of fit of each proposed model to the 
observed data was based on the objective function value, the AIC (Akaike’s information 
criterion), the residual and weighted residual plots and the errors in parameter 
estimation, expressed as the CV (in %). PK and PKPD analysis was achieved by use of 
the compartmental modeling SAAM II software system (SAAM Institute, Seattle, WA, 
USA). 
 
Pharmacokinetic analysis. 
 
The distribution and elimination characteristics of mephedrone were determined after 
the i.v. administration. Fixing the parameters obtained in the i.v. model, p.o. 30 and 60 
mg/kg mephedrone profiles were analyzed simultaneously by using a bicompartmental 
model with oral delay and Michaelis-Menten metabolism kinetics.  The best fit line was 
selected after visual inspection of the fitting, the analysis of the objective function and 
the AIC, the precision of the estimates (mean and CV) and the weighted residuals plot 
analysis.  
 
The i.v. data were described by and open two-compartmental model and fit to the 
following equation: 
 
 
 
Where Cp is the total plasma drug concentration at time t, the terms A and B are the 
extrapolated zero intercepts, and  and  represent the apparent first-order elimination 
rate constants. The half-life (t1/2) for the elimination phase and the volume of 
distribution in the central compartment (Vc) were calculated as follows: t1/2β = 0.693/k10; 
where k10 is an overall elimination rate constant; Vc = Dose/(A+B). For the oral route, 
and absorption rate constant, ka, was fitted. The area under the concentration-time curve 
(AUC0-∞) and area under the first moment of the plasma drug concentration-time curve 
(AUCM0-∞) were calculated by the following equations: 
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

 
The values reported as the Cmax and Tmax are the actual observed values. The F 
(bioavailability) value for oral administration can be calculated by the following 
formula: 
 
 
 
Where, for the oral and i.v. routes Doral and Div are the respective doses; (AUC0-∞) oral 
and (AUC0-∞ ) i.v. are the respective AUCs from 0 to infinity. 
 
Oral pharmacokinetics parameters were calculated with the following equations:   
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Where ka and t1/2,abs are the absorption constant and the absorption constant half-life 
obtained after oral administration. MRT and MAT are the mean resident time and the 
mean absorption time, respectively. The microconstants k12 and k21 used for the 
calculation of Vss are the terms that describe the distribution of the drug between the 
central and peripheral compartments. When Michaelis-Menten fitting was applied, the 
first order elimination constant from the central compartment was substituted by the 
following equation 
 
 
Where Ct is the mephedrone concentration at time t, the Vmax the maximum metabolic 
capacity achieved by the metabolic system and Km the Michaelis-Menten constant. Clmet 
is the metabolic clearance calculated as follows (Barrett et al. 1998): 
 
 
 
Pharmacokinetic/Pharmacodynamic analysis. 
 
A link compartment representing stimulation of the locomotor behavior was used to 
describe the data (Sheiner et al. 1979). Integration of mephedrone pharmacokinetics and 
pharmacodynamics was based on the relationship between mean plasma mephedrone 
concentration-time profile for i.v. and oral dosages. PK/PD modeling was also 
performed by using SAAM II. The effect site was connected by a fixed rate constant 
from the central plasma compartment. A dummy compartment provides the 
concentrations in the effect site (Ce).  The stimulation PK/PD model proposed by the 
sigmoid Emax equation is expressed in terms of Ce such that: 
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The baseline value E0 is the effect when mephedrone concentration is zero. EC50 is the 
concentrations that increase E0 to 50% of the Emax or maximal response and “n” 
determines the sigmoid shape of the function (Hill coefficient) and contributes to the 
steepness of the slope. This produces a PD model that describes the effect as a function 
of time.  
 
Results 
 
Mephedrone pharmacokinetics 
 
The observed plasma concentrations after i.v. administration of mephedrone at each 
time point are shown in Figure 1. Plasma mephedrone was almost undetectable at 4 h 
after administration of this dose. Estimated values for the main pharmacokinetic 
parameters of intravenous administration in rats are presented in Table 1. 
 
The plasma concentrations versus time curve after intravenous administration of 
mephedrone were described by a two-compartment model with significantly different 
distribution and terminal elimination phases (α = 10.23 h-1 and β = 1.86 h-1). 
Pharmacokinetic parameters showed that the t1/2β was 0.37 h. The Clp and the Vss were 
of 1.69 l/h and 2.60 l/kg, respectively (Table 1). 
 
For oral dosing conditions, pharmacokinetic parameters derived from the 
mephedrone plasma concentration curves are summarized in Table 2. Cmax values were 
achieved rapidly showing a Tmax within 0.43 to 0.93 h, plasma concentrations declined 
to undetectable levels at 9 h. Dose-normalized Cmax at 60 mg/kg (16.00 ± 5.70) was 
greater than the observed at 30 mg/kg (11.00 ± 6.93) but did not reach significance. The 
absolute oral bioavailability was 7.30% and 11.20% for 30 and 60 mg/kg respectively.  
 
Normalized AUC0-∞ values by the dose (9.82 ± 0.72 and 14.92 ± 2.87 for 30 and 60 
mg/kg, respectively; p<0.05) show a non-lineal increase. Vmax and Km parameters and 
the calculated Clmet were different for the two oral doses (Table 2). After oral 
administration, the value of Clmet decreased from 77% of total plasma clearance (at the 
dose of 30 mg/Kg) to 20% (at the dose of 60 mg/Kg) showing an oral dose-dependent 
kinetic behavior. 
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Mephedrone protein binding and brain levels 
 
Results from present assays evidenced a percentage of mephedrone protein binding of 
21.59 ± 3.67%. Brain levels of 104.4 ± 17.7 ng mephedrone/g tissue (n = 3) were found. 
A relationship between brain levels and free plasma concentration yielded a ratio of 
1.85 ± 0.08. 
 
Identification of mephedrone and metabolites in rat blood 
 
We have identified five metabolites of mephedrone. These metabolites were detected in 
all collected samples at 30, 60 and 120 min. A description of the identification of 
mephedrone and the observed metabolites is provided below. 
 
Mephedrone 
 
The calculated [M+H+] m/z for mephedrone (C11H15NO) was 178.12319; the found 
[M+H+] m/z was 178.12290 (0.29 mDa). The peak at m/z 160 is attributable to the 
typical H2O loss (18 Da). The loss of methylamine group (31 Da) yielded a fragment 
with low intensity at m/z 147. The presence of the fragment at m/z 119 indicates the 
loss of C3H9N (59 Da), the intensity of which was found to be considerably low.  
 
4-Methylcathinone (4-MC) 
 
We identified the corresponding N-demethylation metabolite, 4-MC, with formula 
C10H13NO. The calculated [M+ H+] m/z was 164.10699; the found [M+ H+] m/z was 
164.10728 (0.29 mDa). The peak at m/z 146 is corresponding to the H2O loss (18 Da). 
The C2H6N loss (45 Da) gave a peak at m/z 119. Both losses suggest that this mass 
spectrum is in accordance with the metabolite structure proposed. 
 
4-Hydroxymethylmethcathinone (4-OH-MMC) 
 
We identified an allylic hydroxylation of mephedrone, the resulting chemical formula of 
which was C11H15NO2. The calculated [M+ H+] m/z was 194.11756; the found [M+ H+] 
m/z was 194.11745 (0.11 mDa). The typical loss of water was also observed giving a 
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peak at m/z 176. Furthermore, we detected a double water-loss (36 Da), suggesting the 
possible presence of a hydroxyl group in this structure. The loss of C3H9N gave a peak 
at m/z 135, indicating that this fragment contains the hydroxyl group previously 
mentioned. Moreover, the double-loss of water leads us to conclude that this group can 
only be found in the allylic position (Fig. 2).  
 
4-Carboxymethylmethcathinone (4-CMMC) 
 
The structure corresponding to the oxidation of 4-OH-MMC was identified; the 
chemical formula for this compound was C11H13NO3; the calculated [M+ H+] m/z was 
208.09737; the found [M+ H+] m/z was 208.09702 (0.35 mDa). In positive ion mode, 
the spectrum showed a peak at m/z 149 (C3H9N loss) indicating the possible presence of 
a carboxybenzoylcation fragment. The detection of a typical carboxylic loss (44 Da) in 
negative ion mode confirmed the proposed structure.  
 
3’-Hydroxy-4-methylmethcathinone (3’-OH-4-MMC) 
 
A compound with chemical formula C11H15NO2 was identified; the calculated [M+H+] 
m/z was 194.11756; the found [M+H+] m/z was 194.11774 (0.19 mDa). The typical loss 
of water was also observed giving a peak at m/z 176. Additionally, a water double-loss 
(36 Da) was detected indicating the possible presence of a hydroxyl group in this 
structure. The loss of the methylbenzoylcation fragment (119 Da) gave a peak at m/z 74, 
which corresponds to a hydroxylated immonium cation thus confirming the proposed 
structure. 
 
?-Hydroxy-4-methylmethcathinone (?-OH-4-MMC) 
 
The metabolite corresponding to an aromatic hydroxylation for mephedrone was 
detected. The chemical formula for this structure was also C11H15NO2; the calculated 
[M+H+] m/z was 194.11756; the found [M+H+] m/z was 194.11773 (0.18 mDa). The 
peak at m/z 135 corresponds to the hydroxylated methylbenzoylcation and the single 
loss of water (peak at m/z 176) suggests that this group is in an undetermined aromatic 
position.  
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We ensured that the mass found did not correspond to endogenous compounds by 
comparing each metabolite mass from treated and untreated rat blood samples. Based on 
the found metabolites, we propose the following phase I metabolic pathway for 
mephedrone, displayed in Figure 3. 
 
Locomotor activity 
 
Intravenous administration of mephedrone induced a significant increase in rat 
locomotor activity (AUC Saline: 8683 ± 98; Mephedrone: 71248 ± 9518; n = 3, p<0.01; 
Student-t test, independent samples) that lasted for 120 min. 
 
Similarly, an overall ANOVA demonstrated a significant effect of oral mephedrone 
on the locomotor activity in rats (F2,8 = 11.261, p<0.01). The post-hoc Tukey-Kramer 
tests, revealed that oral administration of mephedrone increased the locomotor activity 
in a dose-dependent manner (AUC saline: 20760 ± 2002; mephedrone 30 mg/kg: 39778 
± 10255, p<0.05; mephedrone 60 mg/kg: 79692 ± 22302, p<0.01; n = 3). As can be seen 
in Figure 4, this increase is due mainly to a different time-course profile. The higher 
dose (60 mg/kg) induced a maximum break response (2784 ± 901, n = 3) that did not 
differ significantly from that of 30 mg/kg (1802 ± 163, n = 3), but the disappearance of 
the effect becomes much slower; 60 min after the dose of 30 mg/kg breaks values were 
not significantly different from animals treated with saline. At the dose of 60 mg/kg, the 
psychostimulant effect of mephedrone persisted for 90 min. 
 
Pharmacokinetic/Pharmacodynamic analysis. 
 
A plot of locomotor activity versus mephedrone concentrations over time shows a direct 
concentration-effect relationship after i.v. administration (Fig 5a). After oral dosing (Fig 
5b and 5c) a clockwise hysteresis loop was observed, mainly with the highest dose. The 
model shows a mean Emax value of 444.28 ± 200.10 and EC50 values ranging from 65.37 
to 315.44 ng/ml (with a mean value of 0.86 µM) (Table 3). Good agreement between 
predicted and observed values was obtained in accordance to the quality model 
adequacy (mean objective function= 4.35, AIC = 9.54, determined CV <50% for all the 
estimated parameters). 
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Discussion and conclusions 
 
The pharmacokinetics of mephedrone was investigated in adult male Sprague-Dawley 
rats. In this study the increase in locomotor activity induced by mephedrone after i.v. 
and oral administration was characterized and an integrated PK/PD model was 
provided.  
 
A significant increase in locomotor activity (a measure for psychostimulant effects) 
occurred after mephedrone administration and is consistent with the onset of subjective 
effects in humans. Doses reported vary from 15 to 250 mg for oral ingestion and 5 to 
125 mg for nasal insufflation with total doses typically ranging 0.5–2.0 g after redosing 
during a single session. The oral doses used in this study were chosen according to the 
FDA guidelines (Food and Drug Administration, Center for Drug Evaluation and 
Research, 2005) and are equivalent to 336 and 672 mg respectively. 
 
The pharmacokinetics of mephedrone in plasma after i.v. and oral administration was 
well described by a two compartmental open model with and without Michaelis-Menten 
elimination, respectively. The goodness of fit and quality of estimated pharmacokinetic 
parameters were evaluated and confirmed by the objective function, AIC, plot of 
observed versus predicted concentrations and the variation coefficients with values 
lesser than 50%, except for the Vmax value at the highest oral dose where the CV has not 
been estimated. 
 
Our results show that the blood levels of mephedrone declined biphasically after 
intravenous administration. The large apparent Vss indicates that, in rats, mephedrone is 
distributed extensively into tissues. This Vss value was expected of a highly lipophilic 
molecule that must cross the blood brain barrier in order to exert its psychostimulant 
effect.  
 
Compounds with a brain/plasma ratio value greater than 1 freely cross the blood-
brain-barrier (Hitchcock and Pennington 2006). Hence, the obtained value of 
mephedrone brain/plasma ratio of 1.85 demonstrates a high and good central nervous 
system penetration. Moreover this result is in agreement with those obtained by 
Simmler et al. (2012) in an in vitro model of the human blood brain barrier.  
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Comparing the two oral doses, an evident non-linearity in the pharmacokinetics of 
mephedrone was detected using a Michaelis-Menten elimination equation. The non-
linear pharmacokinetics described in the study allows to identify different Vmax and Km 
values, suggesting that the pathways involved in the metabolic clearance may be 
quantitatively and/or qualitatively different depending on the dose. Because the 
metabolic clearance decreased from 77% of total plasma clearance (at the dose of 30 
mg/Kg) to 20% (at the dose of 60 mg/Kg), and taking into account the presence of 
phase I metabolites in plasma, a possible saturation of liver metabolic enzymes and 
pathways is suggested. These results are in agreement with the low oral bioavailability 
observed and suggest that mephedrone undergoes an extensive first pass effect after oral 
administration. Moreover, it is important to note that the low bioavailability of 
mephedrone explains its widespread use snorted rather than taken orally. 
 
This study represents the first qualitative assessment of mephedrone metabolites in 
rats after oral intake. We identified the presence of five metabolites in rat blood at three 
time points after administration (30, 60 and 120 minutes). Based on the obtained data, 
we propose a first step of phase I metabolism for mephedrone, implying an N-
demethylation reaction, yielding the corresponding methylcathinone metabolite. 
Mephedrone undergoes different oxidative reactions including aliphatic and aromatic 
hydroxylation leading to the corresponding 3’-hydroxy-methylmethcathinone or ?-
hydroxy-4-methylmethcathinone metabolites. Khreit et al. (2012) proposed one of these 
metabolites as an unidentified compound named as “compound U”. This is the first time 
that both mephedrone metabolites have been identified in vivo. We also identified 4-
hydroxymethylmethcathinone, a metabolite resulting from an allylic hydroxylation of 
mephedrone, which would subsequently suffer an oxidation, leading to the final 
metabolite 4-carboxymethylmethcathinone 
  
Intravenous and oral administration of mephedrone induced a psychostimulant effect, 
measured as an increase in the locomotor activity in male Sprague-Dawley rats. As we 
have described previously in mice (López-Arnau et al. 2012), after an oral 
administration to rats, a dose-dependent duration of the effect of mephedrone was 
found. It is important to note that the increase in the locomotor activity elicited by 
mephedrone is mainly due to a different time-course profile. The 60 mg/kg dose 
 17 
 
induced a maximum break response which was not significantly different from that of 
30 mg/kg, but the psychostimulant effect lasted longer. This can be explained by the 
saturation of mephedrone metabolism, as mentioned above. 
 
Although more research on the pharmacology and toxicology of abused cathinones is 
needed (Baumann et al. 2012), this study shows new insights into the pharmacokinetic-
pharmacodynamic relationship of mephedrone. By means of this relationship it is 
possible to perform an estimation of the EC50 in the effect compartment and Emax 
parameters, as well as an evaluation of the onset, magnitude and time course of the 
psychostimulant effect. The pharmacodynamics maximum effect was observed 
immediately after mephedrone administration and the decay of the stimulatory effect 
was evaluated from the plot of locomotor activity as a function of mephedrone plasma 
concentrations.  
 
After the i.v. administration, the change in response was directly interpretable as 
function of mephedrone concentration with the use of a sigmoidal Emax model (Csajka 
and Verotta 2006). After oral dosage, plots of mephedrone effect versus observed 
plasma mephedrone concentrations revealed a clockwise hysteresis loop in both oral 
dosages.  A clockwise hysteresis loop has been described after cathinone (Schechter 
1990) or MDMA administration (Hysek et al. 2012) and could be attributable to the 
more rapid distribution of the drug to the brain than to venous blood (Porchet et al. 
1987).  
 
The high brain/plasma ratio obtained in this study suggests that mephedrone freely 
crosses the blood brain barrier, showing an extensive distribution within the brain. 
Previous in vitro results suggest that mephedrone inhibits dopamine, norepinephrine and 
serotonin uptake at concentrations around 1 µM (López-Arnau et al. 2012). These 
results are in close agreement with the EC50 values in the effect site calculated in the 
present study by means of the proposed PKPD model. The low bioavailability of 
mephedrone found after oral ingestion justifies why abusers preferably snort it. 
Mephedrone’s half-life is shorter than that of MDMA (Fonsart et al. 2009), which 
causes users to often redose, thus contributing to the appearance of addiction. Finally, 
the non-linear kinetics after oral administration of mephedrone can cause a dramatic 
increase in plasma levels, leading to enhanced toxicity.  
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In conclusion, the present research provides, for a first time, useful information on 
the in vivo pharmacokinetics, pharmacodynamics and the pharmacokinetic-
pharmacodynamic relationship of mephedrone in rats and will help design new 
experiments in rodents with kinetics-based data as well as offer a better understanding 
of the effects of this drug of abuse in humans. 
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Legends for figures 
 
Fig. 1 Semi-logarithmic plot of experimental and fitted mephedrone plasma levels after 
intravenous (10 mg/kg) and oral (30 and 60 mg/kg) administration. Rats received 
mephedrone at time 0, and blood specimens (0.2 ml) were collected through the external 
jugular vein from 0.08 to 8 h after administration. Mephedrone plasma levels were 
quantitated by LC-MS as described in Materials and Methods section. Data are mean 
for n: 4 to 5 rats/group. 
 
Fig. 2 LC-MS Orbitrap data for fragmentation of mephedrone and their metabolites in 
rat plasma after a single oral dose of 30 mg/Kg at three different times after 
administration (30, 60 and 120 min). Scheme of proposed fragmentation patterns for 
product ions of mephedrone and its metabolites. 
 
Fig. 3 In vivo metabolic pathways proposed for mephedrone in rat plasma after a single 
oral administration of 30 mg/Kg. 
 
Fig. 4 Time-course of locomotor activity induced after oral (30 and 60 mg/kg) and 
intravenous (10 mg/kg) administration of mephedrone. For this behavior, the 
interruption counts were registered, displayed in a 30 min-block. Vertical axis shows 
breaks/animal in 30 minute intervals. Locomotor activity was monitored for 240 min 
and 180 min for oral and intravenous administration, respectively. Data are expressed as 
the mean ± SEM of values from 3 rats. 
 
Fig. 5 Observed plasma concentrations of mephedrone versus observed locomotor 
activity measured each 10 min. Panel a: after intravenous administration (10 mg/kg). 
Panel b: after oral administration (30 mg/kg).  Panel c: after oral administration (60 
mg/kg).  Data points show experimental time (in h) of pharmacokinetic and 
pharmacodynamic data.  
 
 
 
 
